Wastewater Surveillance Pilot at US Military Installations: Cost Model Analysis.

biosurveillance cost cost analysis costs economic economics environment environmental finance financial military health pathogen pathogens public health sanitary sanitation surveillance wastewater wastewater surveillance water

Journal

JMIR public health and surveillance
ISSN: 2369-2960
Titre abrégé: JMIR Public Health Surveill
Pays: Canada
ID NLM: 101669345

Informations de publication

Date de publication:
06 Sep 2024
Historique:
received: 20 11 2023
revised: 23 05 2024
accepted: 30 05 2024
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 6 9 2024
Statut: epublish

Résumé

The COVID-19 pandemic highlighted the need for pathogen surveillance systems to augment both early warning and outbreak monitoring/control efforts. Community wastewater samples provide a rapid and accurate source of environmental surveillance data to complement direct patient sampling. Due to its global presence and critical missions, the US military is a leader in global pandemic preparedness efforts. Clinical testing for COVID-19 on US Air Force (USAF) bases (AFBs) was effective but costly with respect to direct monetary costs and indirect costs due to lost time. To remain operating at peak capacity, such bases sought a more passive surveillance option and piloted wastewater surveillance (WWS) at 17 AFBs to demonstrate feasibility, safety, utility, and cost-effectiveness from May 2021 to January 2022. We model the costs of a wastewater program for pathogens of public health concern within the specific context of US military installations using assumptions based on the results of the USAF and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense pilot program. The objective was to determine the cost of deploying WWS to all AFBs relative to clinical swab testing surveillance regimes. A WWS cost projection model was built based on subject matter expert input and actual costs incurred during the WWS pilot program at USAF AFBs. Several SARS-CoV-2 circulation scenarios were considered, and the costs of both WWS and clinical swab testing were projected. Analysis was conducted to determine the break-even point and how a reduction in swab testing could unlock funds to enable WWS to occur in parallel. Our model confirmed that WWS is complementary and highly cost-effective when compared to existing alternative forms of biosurveillance. We found that the cost of WWS was between US $10.5-$18.5 million less expensive annually in direct costs as compared to clinical swab testing surveillance. When the indirect cost of lost work was incorporated, including lost work associated with required clinical swab testing, we estimated that over two-thirds of clinical swab testing could be maintained with no additional costs upon implementation of WWS. Our results support the adoption of WWS across US military installations as part of a more comprehensive and early warning system that will enable adaptive monitoring during disease outbreaks in a more cost-effective manner than swab testing alone.

Sections du résumé

Background UNASSIGNED
The COVID-19 pandemic highlighted the need for pathogen surveillance systems to augment both early warning and outbreak monitoring/control efforts. Community wastewater samples provide a rapid and accurate source of environmental surveillance data to complement direct patient sampling. Due to its global presence and critical missions, the US military is a leader in global pandemic preparedness efforts. Clinical testing for COVID-19 on US Air Force (USAF) bases (AFBs) was effective but costly with respect to direct monetary costs and indirect costs due to lost time. To remain operating at peak capacity, such bases sought a more passive surveillance option and piloted wastewater surveillance (WWS) at 17 AFBs to demonstrate feasibility, safety, utility, and cost-effectiveness from May 2021 to January 2022.
Objective UNASSIGNED
We model the costs of a wastewater program for pathogens of public health concern within the specific context of US military installations using assumptions based on the results of the USAF and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense pilot program. The objective was to determine the cost of deploying WWS to all AFBs relative to clinical swab testing surveillance regimes.
Methods UNASSIGNED
A WWS cost projection model was built based on subject matter expert input and actual costs incurred during the WWS pilot program at USAF AFBs. Several SARS-CoV-2 circulation scenarios were considered, and the costs of both WWS and clinical swab testing were projected. Analysis was conducted to determine the break-even point and how a reduction in swab testing could unlock funds to enable WWS to occur in parallel.
Results UNASSIGNED
Our model confirmed that WWS is complementary and highly cost-effective when compared to existing alternative forms of biosurveillance. We found that the cost of WWS was between US $10.5-$18.5 million less expensive annually in direct costs as compared to clinical swab testing surveillance. When the indirect cost of lost work was incorporated, including lost work associated with required clinical swab testing, we estimated that over two-thirds of clinical swab testing could be maintained with no additional costs upon implementation of WWS.
Conclusions UNASSIGNED
Our results support the adoption of WWS across US military installations as part of a more comprehensive and early warning system that will enable adaptive monitoring during disease outbreaks in a more cost-effective manner than swab testing alone.

Identifiants

pubmed: 39240545
pii: v10i1e54750
doi: 10.2196/54750
doi:

Substances chimiques

Wastewater 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e54750

Informations de copyright

© Jaleal S Sanjak, Erin M McAuley, Justin Raybern, Richard Pinkham, Jacob Tarnowski, Nicole Miko, Bridgette Rasmussen, Christian J Manalo, Michael Goodson, Blake Stamps, Bryan Necciai, Shanmuga Sozhamannan, Ezekiel J Maier. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org).

Auteurs

Jaleal S Sanjak (JS)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Erin M McAuley (EM)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Justin Raybern (J)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Richard Pinkham (R)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Jacob Tarnowski (J)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Nicole Miko (N)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Bridgette Rasmussen (B)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Christian J Manalo (CJ)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Michael Goodson (M)

United State Air Force Research Laboratory, Wright Patterson Air Force Base, OH, United States.

Blake Stamps (B)

United State Air Force Research Laboratory, Wright Patterson Air Force Base, OH, United States.

Bryan Necciai (B)

Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, Frederick, MD, United States.

Shanmuga Sozhamannan (S)

Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, Frederick, MD, United States.
Joint Research and Development, Inc, Stafford, VA, United States.

Ezekiel J Maier (EJ)

Booz Allen Hamilton, 4747 Bethesda Ave, Bethesda, MD, United States, 1 5712413499.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH